Morgan Stanley Maintains Overweight on Elevance Health, Raises Price Target to $587
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ha maintains an Overweight rating on Elevance Health (NYSE:ELV) and raises the price target from $585 to $587.
October 19, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Elevance Health and raises the price target from $585 to $587, indicating a positive outlook for the company.
The raised price target by Morgan Stanley indicates a positive outlook for Elevance Health. This could potentially lead to an increase in the company's stock price in the short term as it shows the analyst's confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100